A Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying
Phase of Trial: Phase II
Latest Information Update: 26 Dec 2017
At a glance
- Drugs Camicinal (Primary)
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 26 Dec 2017 Results published in the Movement Disorders Journal.
- 30 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 16 May 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.